2022 World Conference on Lung Cancer (ePosters)-EP08.02-128. Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial

EP08.02-128. Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial

Back to course

Pdf Summary

The document discusses the results of a phase I/IIa randomized controlled trial that evaluated the efficacy of autologous ex-vivo expanded NK cell (SNK01) treatment combined with pembrolizumab in advanced non-small cell lung cancer (NSCLC). The study found that the combination treatment showed better efficacy than pembrolizumab monotherapy in terms of overall survival (OS) and progression-free survival (PFS) at the 2-year follow-up. The estimated 2-year survival rate for the combination treatment was 58.3% compared to 16.7% for pembrolizumab monotherapy, with a hazard ratio (HR) of 0.32. The median PFS was 6.2 months for the combination treatment compared to 1.7 months for monotherapy, with a significantly higher PFS and HR of 0.15. Additionally, the document mentions that a larger study is needed to confirm these results. <br /><br />In terms of the different doses of SNK01, the study found that there was no statistically significant difference between the low-dose (2 x 109 cells/dose) and high-dose (4 x 109 cells/dose) SNK01 groups in terms of 2-year survival rates or PFS. <br /><br />The trial included 20 patients with advanced NSCLC who had a PD-L1 tumor proportion score of 1% or greater and had failed prior first-line platinum-based therapy. The patients were divided into three groups: low-dose SNK01 plus pembrolizumab, high-dose SNK01 plus pembrolizumab, and pembrolizumab monotherapy. The primary endpoint of the study was overall survival, and the secondary endpoint was progression-free survival. <br /><br />Overall, the study suggests that autologous ex-vivo expanded NK cell treatment combined with pembrolizumab may improve long-term outcomes in advanced NSCLC patients. However, further research is needed to validate these findings.

Asset Subtitle

Hyungjun Park

Meta Tag

Speaker Hyungjun Park

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

autologous ex-vivo expanded NK cell

SNK01

pembrolizumab

non-small cell lung cancer

NSCLC

randomized controlled trial

overall survival

progression-free survival

2-year follow-up

hazard ratio